Cassava Sciences Warrants(SAVAW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SAVAW Cassava Sciences Warrants

Pre-Market Trading 11-22 07:58:47 EST

0.0300

+0.0000

0.00%

High0.0300	Low0.0300	Vol0.00
Open0.0300	D1 Closing0.0300	Amplitude0.00%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O0.00	T/O Rate--	Tradable Shares0.00
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SAVAW","market":"US","secType":"WAR","nameCN":"Cassava Sciences Warrants","latestPrice":0.03,"timestamp":1732222800000,"preClose":0.03,"halted":0,"volume":0,"delay":0,"strike":33,"lastTradingDate":1731646800000,"nameEN":"Cassava Sciences Warrants","floatShares":0,"shares":0,"eps":0,"marketStatus":"Pre-Market Trading","change":0,"latestTime":"11-22 07:58:47 EST","open":0.03,"high":0.03,"low":0.03,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732285800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.03,"volumeRatio":0,"lotSize":1,"type":1,"expireDate":1731646800000,"ul":"SAVA","ulStockBrief":{"symbol":"SAVA","market":"US","secType":"STK","nameCN":"Cassava Sciences Inc","latestPrice":32.18,"timestamp":1732222800000,"preClose":26.05,"halted":0,"volume":4650444,"hourTrading":{"tag":"盘前","latestPrice":31.75,"preClose":32.18,"latestTime":"07:55 EST","volume":6378,"amount":213150.09399599998,"timestamp":1732280152564},"delay":0}},"requestUrl":"/m/hq/s/SAVAW/wiki","defaultTab":"wiki","newsList":[{"id":"2483041323","title":"Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2483041323","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483041323?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:40","pubTimestamp":1731681610,"startTime":"0","endTime":"0","summary":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Cassava Sciences, Inc.  is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole?By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Cassava Sciences, Inc. is one of 1024 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. C","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/aMCT_Lh5K9xNn9.QUdX03w--~B/aD01ODc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/17a4db66bb13bdabcbf848550a6ea15a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/aMCT_Lh5K9xNn9.QUdX03w--~B/aD01ODc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/17a4db66bb13bdabcbf848550a6ea15a"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cassava-sciences-sava-outperforming-other-144010455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SAVA","SAVAW"],"gpt_icon":0},{"id":"2479818350","title":"Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2479818350","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479818350?lang=en_us&edition=fundamental","pubTime":"2024-10-31 20:30","pubTimestamp":1730377800,"startTime":"0","endTime":"0","summary":"Conference call and webcast to begin at 8:30 AM ET. AUSTIN, Texas, Oct. 31, 2024  -- Cassava Sciences, Inc. , a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time.A replay of the audio webcast will also be available on the “Company Presentations” page of the Cassava Sciences website for 90 days following the webcast.About Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease.Simufilam is Cassava Sciences’ small molecule oral drug candidate currently in Phase 3 clinical trials for the treatment of Alzheimer's disease. Simufilam targets a specific site on filamin A, a scaffolding protein that is critical to certain receptor interactions in the brain.Cassava Sciences believes that simufilam interrupts amyloid-β42 binding to recep","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bJl98QTyU0hrC.haxFxmAg--~B/aD03NzM7dz0xMzczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/21979d6015cfbdfe43b479a193b60718","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bJl98QTyU0hrC.haxFxmAg--~B/aD03NzM7dz0xMzczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/21979d6015cfbdfe43b479a193b60718"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cassava-sciences-report-third-quarter-123000951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4547","BK4007","SAVA","BK4585","SAVAW"],"gpt_icon":0},{"id":"2479786745","title":"Institutions along with individual investors who hold considerable shares inCassava Sciences, Inc. (NASDAQ:SAVA) come under pressure; lose 6.7% of holdings value","url":"https://stock-news.laohu8.com/highlight/detail?id=2479786745","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479786745?lang=en_us&edition=fundamental","pubTime":"2024-10-30 21:47","pubTimestamp":1730296057,"startTime":"0","endTime":"0","summary":"Cassava Sciences' significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public. 36% of the business is held by the top 25 shareholders. If you want to know who really controls Cassava Sciences, Inc. , then you'll have to look at the makeup of its share registry. With 60% stake, individual investors possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises .While institutions who own 29% came under pressure after market cap dropped to US$1.3b last week,individual investors took the most losses.In the chart below, we zoom in on the different ownership groups of Cassava Sciences.While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/institutions-along-individual-investors-hold-134737700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4547","LU2210150020.SGD","NQmain","NDAQ","BK4585","BK4112","SQQQ","TQQQ",".IXIC","IE00B3QW5Z07.USD","IE00BKPKM429.USD","MNQmain","IE00BGHQF748.EUR","LU2210149790.SGD","BK4007","LU2095319765.USD","IE00B64PRP62.GBP","QLD","BK4588","SAVAW","SAVA","PSQ","QID"],"gpt_icon":1},{"id":"2479437743","title":"MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2479437743","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479437743?lang=en_us&edition=fundamental","pubTime":"2024-10-29 01:40","pubTimestamp":1730137258,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc.  stock is trading higher on Monday after the company released new preclinical findings from Ketamir-2, a novel oral ketamine analog.The new preclinical data show that Ketamir-2 is 60% more effective than the FDA-approved neuropathic pain treatment gabapentin in reducing chemotherapy-induced pain.Also Read: MIRA Pharmaceuticals’ Oral Ketamine Analog Achieves Complete Normalization Of Neuropathic Pain In Animal Studies. On Day 9, at the optimal dose of 300 mg/kg, Ketamir-2 led to near-complete normalization of pain sensitivity, outperforming FDA-approved gabapentin by 60%, which provided only moderate relief.To maximize the development timeline, MIRA is considering conducting multiple Phase 2 trials in parallel, specifically targeting neuropathic pain across different patient populations, which could further accelerate Ketamir-2’s path to market.In addition to the ongoing studies, MIRA is in the process of submitting several scientific journal publications that","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/92kmnbogljGXGlbq7JI58A--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/504361aa1cf5cd6d696519cc9da86e9f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/92kmnbogljGXGlbq7JI58A--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/504361aa1cf5cd6d696519cc9da86e9f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-formulated-shows-greater-174058339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VFF","MIRA","BK4189","SAVA","SAVAW","BK4007"],"gpt_icon":0},{"id":"2476349905","title":"Cassava Sciences, Inc. (SAVA): Jim Cramer Says Eli Lilly Has The Edge","url":"https://stock-news.laohu8.com/highlight/detail?id=2476349905","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476349905?lang=en_us&edition=fundamental","pubTime":"2024-10-18 09:19","pubTimestamp":1729214375,"startTime":"0","endTime":"0","summary":"We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are going to take a look at where Cassava Sciences, Inc.  stands against other stocks discussed by Jim Cramer during the latest lightning round.On Tuesday, Jim Cramer, host of Mad Money, shared his thoughts on the market’s recent volatility and offered advice to investors regarding earnings reports. He cautioned against making trades based solely on immediate stock reactions following earnings announcements, as many of these movements might not be justified.Cramer emphasized his mission to guide individuals toward becoming more thoughtful investors, rather than impulsive traders. He noted that the Dow Jones Industrial Average dropped 325 points, while the S&P 500 declined by 0.76%, and the Nasdaq Composite fell 1.01%.For this article, we compiled a list of 12 stocks that were discussed by Cramer during lightning rounds of Mad Money’s episodes on October 14, 15, and 16. ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/4LJX_tTJ1ix5Uuec83n.Nw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8edf2a40d71f585c4886ccb95dda369c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/4LJX_tTJ1ix5Uuec83n.Nw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8edf2a40d71f585c4886ccb95dda369c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cassava-sciences-inc-sava-jim-011935323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LLY","LU0320765059.SGD","LU0238689110.USD","IE00B2B36J28.USD","BK4516","LU0471298777.SGD","LU0820561909.HKD","LU1061106388.HKD","IE00BJT1NW94.SGD","LU1035775433.USD","BK4588","LU0471298694.HKD","LU0672654240.SGD","QID","GB00BDT5M118.USD","LU0466842654.USD","LU0943347566.SGD","IE00BJLML261.HKD","LU0096364046.USD","LU0640476718.USD","LU0689472784.USD","IE0009355771.USD","QLD","BK4581","LU0058720904.USD","LU0456855351.SGD","SAVAW","LU1023059063.AUD","TQQQ","BK4539","IE0004445239.USD","LU0354030511.USD","PSQ","MNQmain","LU0006306889.USD","NQmain","LU0256863811.USD","LU0198837287.USD","LU0354030438.USD","LU0882574139.USD","IE00BFTCPJ56.SGD","LU0203202063.USD","COMP","BK4007","LU0203201768.USD","LU0820561818.USD","SQQQ",".IXIC","IE0002141913.USD","SAVA"],"gpt_icon":1},{"id":"2474421632","title":"Cassava Sciences Advances Alzheimer’s Trials Amid SEC Settlement","url":"https://stock-news.laohu8.com/highlight/detail?id=2474421632","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474421632?lang=en_us&edition=fundamental","pubTime":"2024-10-09 20:29","pubTimestamp":1728476978,"startTime":"0","endTime":"0","summary":"Rick Barry, CEO of Cassava Sciences, updated the community on the company’s progress, particularly regarding the ReTHINK Phase 3 clinical trial for Alzheimer’s, which has completed patient dosing and is awaiting data analysis. Notably, the ReTHINK and upcoming ReFOCUS trials are independent of each other, enhancing the credibility of their results. Amid these advancements, Cassava settled with the SEC, paying a $40 million penalty for inaccurately disclosed information, allowing the company to concentrate on simufilam’s development. Despite setbacks, Cassava remains committed to improving corporate governance and is optimistic about providing an effective Alzheimer’s treatment.See more data about SAVA stock on TipRanks’ Stock Analysis page.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tXfTVJ1OixCCbB5e.FsdJg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/38a68defd725ddd544390055e985cfb8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tXfTVJ1OixCCbB5e.FsdJg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/38a68defd725ddd544390055e985cfb8"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cassava-sciences-advances-alzheimer-trials-122938273.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cassava-sciences-advances-alzheimer-trials-122938273.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","SAVA","BK4588","BK4007","BK4547","SAVAW"],"gpt_icon":0},{"id":"2473046471","title":"What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2473046471","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473046471?lang=en_us&edition=fundamental","pubTime":"2024-10-08 22:57","pubTimestamp":1728399424,"startTime":"0","endTime":"0","summary":"The SEC alsochargedHoau-Yan Wang, a consultant and co-developer of the drug, with manipulating trial results.In an open letter, Cassava President and CEO Rick Barry emphasized that the settlement, though financially significant, was necessary for the company to refocus its efforts.The firm expressed that this decision allows it to concentrate on simufilam’s development without ongoing distractions from regulatory issues.The SEC’s investigation found that inSeptember 2020, Cassava disclosed manipulated data from the trial, which falsely suggested dramatic improvements in Alzheimer’s biomarkers like total tau and phosphorylated tau.The CEO added, “In sum, we have been able to put the SEC's three-year investigation of Cassava behind us by agreeing to settle a charge of negligently making inaccurate disclosures related to our 2020 Phase 2b clinical study and paying a $40 million monetary penalty. In addition, we do not anticipate that the Department of Justice will charge the company or se","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YexmaagLjksdxdjfUCpTRw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/0b66022de8513dc50b4ff7c66434505c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YexmaagLjksdxdjfUCpTRw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/0b66022de8513dc50b4ff7c66434505c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/whats-going-alzheimers-focused-cassava-145704485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4547","BK4585","SAVA","BK4007","SAVAW"],"gpt_icon":0},{"id":"2472235333","title":"SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2472235333","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472235333?lang=en_us&edition=fundamental","pubTime":"2024-09-30 22:05","pubTimestamp":1727705100,"startTime":"0","endTime":"0","summary":"Cassava Sciences SAVA has agreed to pay a $40 million fine to settle charges from the U.S. Securities and Exchange Commission  over allegedly misleading statements about the results of its 2020 mid-stage study of simufilam for Alzheimer’s disease. Despite settling, the company did not admit to or deny the SEC’s allegations.The SEC also brought charges against two former senior executives, including founder and ex-CEO Remi Barbier and former senior vice president of Neuroscience, Dr. Lindsay Burns. They were accused of negligence in their disclosures regarding the study of simufilam and agreed to pay fines of $175,000 and $85,000, respectively, to resolve the claims.Shares of Cassava lost 10.6% following the settlement news. Regarding the previously disclosed investigation by the Department of Justice , SAVA stated that it currently does not expect the DOJ's Criminal Division to file charges against or pursue a settlement with the company.Year to date, shares of Cassava have risen 26.5%","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OQmIpr5vwbHDcZeUdtSZeA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a85ded772dcf5689bab3fdbf2b5da21","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OQmIpr5vwbHDcZeUdtSZeA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a85ded772dcf5689bab3fdbf2b5da21"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sava-stock-down-settling-misleading-140500589.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4588","BK4585","BK4007","KRYS","BK4547","FULC","SAVAW","SAVA","ANIP"],"gpt_icon":0},{"id":"2471382620","title":"Company News for Sep 30, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2471382620","media":"Zacks","labels":["Product Release","Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471382620?lang=en_us&edition=fundamental","pubTime":"2024-09-30 21:18","pubTimestamp":1727702280,"startTime":"0","endTime":"0","summary":"Bristol-Myers Squibb Company  shares rose 1.6% after the FDA approved its new drug for schizophrenia.Shares of Cassava Sciences  plunged 10.6% after the company reached a $40 million settlement with U.S. securities regulators over charges of making misleading claims about an Alzheimer’s clinical trial.EchoStar Corporation  jumped 8.9% on reports of advanced merger talks between its Dish unit and DirecTV, including Dish’s Sling TV.Costco Wholesale Corporation  shares fell 1.8% after the company reported fourth-quarter fiscal 2024 revenues of $79.7 billion, missing the Zacks Consensus Estimate by 0.07%.Want the latest recommendations from Zacks Investment Research?Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report. Bristol Myers Squibb Company  : Free Stock Analysis Report. To read this article on Zacks.com click here.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tdykziZpl44jUPQqI7k0_g--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8127f43af74d394c31adc7eb2e1fa286","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tdykziZpl44jUPQqI7k0_g--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8127f43af74d394c31adc7eb2e1fa286"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/company-news-sep-30-2024-131800206.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1670711040.USD","LU1670711123.USD","LU0225284248.USD","LU2360032135.SGD","BK4588","LU0417517546.SGD","LU1496350502.SGD","LU1066053197.SGD","LU2237438978.USD","LU0385154629.USD","LU0820561818.USD","LU1496350171.SGD","IE00B2B36J28.USD","LU0306807586.USD","LU2125154778.USD","SAVA","BMY","LU0471298777.SGD","IE00BKVL7J92.USD","LU2210150020.SGD","LU1670710661.SGD","LU2210149790.SGD","LU1670710588.SGD","LU0820561909.HKD","LU2242646821.SGD","LU0985481810.HKD","IE00BFTCPJ56.SGD","IE00BSNM7G36.USD","LU1430594728.SGD","LU2133065610.SGD","SATS","LU0306806265.USD","LU0234570918.USD","IE0009355771.USD","BK4581","LU0689472784.USD","LU2095319765.USD","LU0114720955.EUR","LU0456855351.SGD","BK4585","COST","BK4504","LU2360106947.USD","SAVAW","LU1032466523.USD","LU1069344957.HKD","LU1718418525.SGD","BK4089","LU1291159041.SGD","LU0234572021.USD"],"gpt_icon":1},{"id":"2470208898","title":"Cassava Sciences shares drop in pre-open trade after $40 mln SEC settlement","url":"https://stock-news.laohu8.com/highlight/detail?id=2470208898","media":"Investing.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470208898?lang=en_us&edition=fundamental","pubTime":"2024-09-27 20:48","pubTimestamp":1727441291,"startTime":"0","endTime":"0","summary":"Investing.com -- Shares of Cassava Sciences, Inc dropped 11.5% in pre-open trade on Friday following the company's statement that it has reached a $40 million settlement with the U.S. Securities and Exchange Commission  over negligence-based disclosure charges.The charges stem from an SEC investigation into statements made by the company regarding the results of its 2020 Phase 2b clinical trial of simufilam, an experimental treatment for Alzheimer’s disease.Cassava Sciences, Inc. settled the charges with the SEC, agreeing to pay a $40 million penalty, without admitting or denying the SEC’s allegations.Cassava stated that it fully cooperated with the SEC and has since implemented remedial measures. The $40 million penalty will impact the company's financials for the second half of 2024.Cassava also addressed a separate investigation by the U.S. Department of Justice , stating that it does not expect criminal charges or a resolution to be brought by the DOJ’s Criminal Division.Exclusive-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cassava-sciences-shares-drop-pre-124811021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4547","BK4007","BK4588","SAVA","SAVAW"],"gpt_icon":0},{"id":"2470570020","title":"SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty","url":"https://stock-news.laohu8.com/highlight/detail?id=2470570020","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470570020?lang=en_us&edition=fundamental","pubTime":"2024-09-27 20:28","pubTimestamp":1727440083,"startTime":"0","endTime":"0","summary":"Alzheimer’s drug developer Cassava Sciences Inc , its founder Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns have agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company’s controversial Alzheimer’s drug, simufilam.The SEC also charged Hoau-Yan Wang, a consultant and co-developer of the drug, with manipulating trial results.The SEC’s investigation found that in September 2020, Cassava disclosed manipulated data from the trial, which falsely suggested dramatic improvements in Alzheimer’s biomarkers like total tau and phosphorylated tau.According to the SEC, Dr. Wang, who was unblinded to certain trial data, used this knowledge to select a subset of patients, creating an illusion of significant efficacy.Cassava later published this manipulated data in a press release and investor deck.Further allegations highlight that Cassava and its executives, including Barbier and Burns, misled investors by promoting ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_bMSjamUvY9IaCyIeeYIYg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/146d1d73eb3b769e2f1f0009acb1c92c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_bMSjamUvY9IaCyIeeYIYg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/146d1d73eb3b769e2f1f0009acb1c92c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sec-charges-cassava-sciences-over-122803570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADC","BK4588","BK4007","BK4585","BK4547","BK4231","SAVAW","BK4080","SAVA"],"gpt_icon":0},{"id":"2470715619","title":"Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2470715619","media":"Bloomberg","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470715619?lang=en_us&edition=fundamental","pubTime":"2024-09-27 07:11","pubTimestamp":1727392305,"startTime":"0","endTime":"0","summary":" -- Drugmaker Cassava Sciences Inc. and two former executives agreed to pay more than $40 million to resolve US Securities and Exchange Commission claims they misled the public about the success of an Alzheimer’s drug trial.Cassava published results in 2020 based on hand-selected data that showed patients’ memories improved, though the full data showed no measurable progress, the SEC said in a statement Thursday announcing the settlement. The company later raised hundreds of millions of dollars in funding, the regulator said.“Our capital markets can and should be a powerful engine for innovation in the development of new and potentially life-altering therapeutics,” said Mark Cave, associate director of the SEC’s enforcement division.The company, which the SEC accused of violating antifraud provisions of federal securities laws, will shoulder the vast majority of the punishment — $40 million — in an agreement subject to a judge’s approval, the regulator said.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/IqoUI2XLCxso8pApFmPtKw--~B/aD0zOTU7dz01OTQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_markets_842/aaf3673a4a072d1645ac4e77fa5b7f12","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/IqoUI2XLCxso8pApFmPtKw--~B/aD0zOTU7dz01OTQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_markets_842/aaf3673a4a072d1645ac4e77fa5b7f12"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cassava-pay-40-million-sec-231145794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","SAVAW","BK4007","BK4547","BK4585","SAVA"],"gpt_icon":0},{"id":"2470799019","title":"Cassava Sciences Resolves SEC Investigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2470799019","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470799019?lang=en_us&edition=fundamental","pubTime":"2024-09-27 06:15","pubTimestamp":1727388900,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, Sept. 26, 2024  -- Cassava Sciences, Inc.  , a biotechnology company focused on Alzheimer’s disease, today announced that it has reached a settlement with the U.S. Securities and Exchange Commission  of negligence-based disclosure charges that resolve a previously-disclosed SEC investigation into statements made by the Company pertaining to the results of its 2020 Phase 2b clinical trial of simufilam and related matters. Two former senior employees of the Company also settled negligence-based disclosure charges brought by the SEC.Cassava, without admitting or denying the SEC’s allegations, agreed to pay a monetary penalty of $40 million. The Company cooperated fully with the SEC’s investigation and has implemented remedial measures.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bJl98QTyU0hrC.haxFxmAg--~B/aD03NzM7dz0xMzczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/21979d6015cfbdfe43b479a193b60718","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bJl98QTyU0hrC.haxFxmAg--~B/aD03NzM7dz0xMzczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/21979d6015cfbdfe43b479a193b60718"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cassava-sciences-resolves-sec-investigation-221500393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SAVA","BK4007","BK4588","BK4547","BK4585","SAVAW"],"gpt_icon":0},{"id":"2470296353","title":"Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2470296353","media":"Zacks","labels":["Product Release","Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470296353?lang=en_us&edition=fundamental","pubTime":"2024-09-25 23:45","pubTimestamp":1727279100,"startTime":"0","endTime":"0","summary":"Eli Lilly LLY announced that its Alzheimer's disease  drug Kisunla  has been approved for use in Japan. The drug will treat early symptomatic AD in adults with mild cognitive impairment  and those with the mild dementia stage of AD, with confirmed amyloid pathology.Japan is the second major market in which Kisunla has been approved for use. LLY received its first approval for the drug in the United States this July.Both these approvals are based on data from the TRAILBLAZER-ALZ 2 phase III study, which showed that treatment with Kisunla slowed cognitive and functional decline by up to 35% in patients with less advanced disease compared to placebo at 18 months. It also showed that Kisunla reduced participants' risk of progressing to the next clinical stage of disease by up to 39%. A monthly intravenous infusion of Kisunla reduced amyloid plaques on average by 84% at 18 months compared with the start of the study in the overall population of participants.The AD target market is highly co","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qi8AmKRuXk4zL7mGsiR5yg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qi8AmKRuXk4zL7mGsiR5yg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eli-lilly-secures-approval-alzheimers-154500244.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B1BXHZ80.USD","IE00BJJMRZ35.SGD","IE00BK4W5L77.USD","IE00BJLML261.HKD","LU0238689110.USD","LU0354030511.USD","LLY","LU1551013342.USD","MCI","IE0004445239.USD","BK4532","PRTA","LU0061475181.USD","LU0109391861.USD","LU1035775433.USD","IE0002141913.USD","BK4516","IE00BK4W5M84.HKD","LU0094547139.USD","BK4533","LU0256863811.USD","LU0058720904.USD","IE00B19Z9Z06.USD","SAVAW","LU0234570918.USD","BIIB","IE00BJT1NW94.SGD","LU0006306889.USD","BK4007","LU1061106388.HKD","SAVA","LU0417517546.SGD","LU0079474960.USD","LU0122379950.USD","LU0320765992.SGD","LU0672654240.SGD","GB00BDT5M118.USD","LU0106261372.USD","IE00B894F039.SGD","IE00B19Z9P08.USD","LU1023059063.AUD","BK4534","LU0354030438.USD","LU0708995401.HKD","LU1280957306.USD","LU0256863902.USD","LU0289739699.SGD","LU0471298694.HKD","LU1057294990.SGD","LU0882574055.USD","BK4585"],"gpt_icon":1},{"id":"2464803495","title":"Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2464803495","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464803495?lang=en_us&edition=fundamental","pubTime":"2024-09-03 20:31","pubTimestamp":1725366660,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, Sept. 03, 2024  -- Cassava Sciences, Inc. , a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present at the H.C. Wainwright 26th Annual Global Investment Conference, being held in New York.Rick Barry, Cassava’s Executive Chairman, will join in a ‘fireside chat’ with Vernon T. Bernardino, PhD., Managing Director, Biotechnology Equity Research, at H.C. Wainwright.Institutional investors who are registered for this conference may log into www.hcwevents.com to request a meeting with Cassava Sciences, pending availability.Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our novel science is based on stabilizing—but not removing—a critical protein in the brain.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bJl98QTyU0hrC.haxFxmAg--~B/aD03NzM7dz0xMzczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/21979d6015cfbdfe43b479a193b60718","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bJl98QTyU0hrC.haxFxmAg--~B/aD03NzM7dz0xMzczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/21979d6015cfbdfe43b479a193b60718"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cassava-sciences-present-h-c-123100208.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SAVAW","SAVA"],"gpt_icon":0},{"id":"2460766077","title":"Silicon Motion Technology Corporation (SAVA): Evaluating Its Position Among Top Debt-Free Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2460766077","media":"Insider Monkey","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460766077?lang=en_us&edition=fundamental","pubTime":"2024-08-18 10:44","pubTimestamp":1723949055,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 7 Best Debt Free Stocks To Buy. In this article, we are going to take a look at where Cassava Sciences Inc  stands against the other debt free stocks.However, during the Federal Reserve’s meeting on July 30-31, 2024, interest rates were kept unchanged at 5.25% – 5.50%. Officials noted that inflation is nearing its target, potentially allowing for future rate cuts. “The Committee judges that the risks to achieving its employment and inflation goals continue to move into better balance,” the Federal Open Market Committee stated. Chair Jerome Powell mentioned that a rate cut could be possible in September if inflation continues to ease.While most people might argue that companies with zero debt are not optimizing their capital structures for growth, that’s only sometimes the case. The best debt-free stocks to buy are companies with solid balance sheets owing to their strong free cash flow generation capabilities. It also affirms the resiliency of the com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/4LJX_tTJ1ix5Uuec83n.Nw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8edf2a40d71f585c4886ccb95dda369c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/4LJX_tTJ1ix5Uuec83n.Nw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8edf2a40d71f585c4886ccb95dda369c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/silicon-motion-technology-corporation-sava-024415435.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","US2Y.BOND","US5Y.BOND","US912797GL51.BOND","US30Y.BOND","US912797HE00.BOND","BK4007","US12M.BOND","BK4588","NQmain","US7Y.BOND","US3Y.BOND","SIMO","US10Y.BOND",".IXIC","BK4141","QID","SQQQ","BK4547","US6M.BOND","SAVA","MNQmain","BK4526","PSQ","US912797GW17.BOND","QLD","SAVAW","TQQQ"],"gpt_icon":1},{"id":"2458835396","title":"Cassava Sciences, Inc. (NASDAQ:SAVA): Is Breakeven Near?","url":"https://stock-news.laohu8.com/highlight/detail?id=2458835396","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458835396?lang=en_us&edition=fundamental","pubTime":"2024-08-10 21:09","pubTimestamp":1723295370,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Cassava Sciences, Inc.'s  future prospects. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. The US$1.2b market-cap company posted a loss in its most recent financial year of US$97m and a latest trailing-twelve-month loss of US$15m shrinking the gap between loss and breakeven. The most pressing concern for investors is Cassava Sciences' path to profitability – when will it breakeven?Below we will provide a high-level summary of the industry analysts’ expectations for the company.Consensus from 2 of the American Pharmaceuticals analysts is that Cassava Sciences is on the verge of breakeven. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$85m in 2025. The company is therefore projected to breakeven just over a year from now. In order to meet this breakeven date, we calculated the ra","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cassava-sciences-inc-nasdaq-sava-130930788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4112","NDAQ","NQmain","IE00BKPKM429.USD","LU2095319765.USD","MNQmain","SAVA","TQQQ","QLD","BK4585","BK4547","BK4007",".IXIC","QID","PSQ","BK4588","SQQQ","LU2210150020.SGD","SAVAW","LU2210149790.SGD"],"gpt_icon":1},{"id":"2457339238","title":"Cassava Sciences Reports Q2 2024  Financial Results and Operational Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2457339238","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457339238?lang=en_us&edition=fundamental","pubTime":"2024-08-08 20:00","pubTimestamp":1723118400,"startTime":"0","endTime":"0","summary":"$207.3 Million in Cash and Cash Equivalents at June 30, 2024.Company in Advanced Discussions to Resolve SEC Investigation. $40 Million Estimated Loss Contingency Recorded in Q2 for Resolution.Conference Webcast Scheduled for Today at 8:30AM ET.Phase 3 Trials – Our first Phase 3 study, called RETHINK-ALZ, is designed to evaluate the safety and efficacy of simufilam 100 mg tablets twice-daily versus matching placebo over 52 weeks .Our second Phase 3 study, called REFOCUS-ALZ, is designed to evaluate the safety and efficacy of oral simufilam 100 mg and 50 mg tablets twice-daily versus matching placebo over 76 weeks . Clinical sites are in the United States, Canada, Puerto Rico, Australia, and South Korea. P","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bJl98QTyU0hrC.haxFxmAg--~B/aD03NzM7dz0xMzczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/21979d6015cfbdfe43b479a193b60718","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bJl98QTyU0hrC.haxFxmAg--~B/aD03NzM7dz0xMzczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/21979d6015cfbdfe43b479a193b60718"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cassava-sciences-reports-q2-2024-120000961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SAVAW","SAVA"],"gpt_icon":0},{"id":"2455436939","title":"Cassava Sciences Announces Expansion of Open-Label Extension Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2455436939","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2455436939?lang=en_us&edition=fundamental","pubTime":"2024-07-30 20:15","pubTimestamp":1722341700,"startTime":"0","endTime":"0","summary":"Ongoing open-label extension trials of simufilam in Alzheimer’s disease to be extended by up to an additional 36 months.The extension provides participants the opportunity to continue on treatment, if they desire, pending results of the ongoing pivotal Phase 3 trials.Company plans to add cognition and plasma biomarker monitoring to the open-label extension trials to gather additional long-term data on simufilam treatment.Ongoing Phase 3 Studies of Simufilam in Alzheimer’s DiseaseCassava is currently running two double-blind, randomized, placebo-controlled studies of simufilam in patients with mild-to-moderate Alzheimer’s disease dementia. RETHINK-ALZ is a 52-week trial in which 804 patients were randomized 1:1 between simufilam 100 mg and placebo. REFOCUS-ALZ is a 76-week trial in which 1,125 patients were randomized 1:1:1 between simufilam 100 mg, simufilam 50 mg, and placebo. The trials are being conducted at 172 clini","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bJl98QTyU0hrC.haxFxmAg--~B/aD03NzM7dz0xMzczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/21979d6015cfbdfe43b479a193b60718","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bJl98QTyU0hrC.haxFxmAg--~B/aD03NzM7dz0xMzczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/21979d6015cfbdfe43b479a193b60718"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cassava-sciences-announces-expansion-open-121500799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SAVA","SAVAW","BK4007","BK4547","BK4585","BK4588"],"gpt_icon":0},{"id":"2452501435","title":"Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2452501435","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2452501435?lang=en_us&edition=fundamental","pubTime":"2024-07-18 21:38","pubTimestamp":1721309880,"startTime":"0","endTime":"0","summary":"It was a regular week for the biotech sector with quite a few important pipeline and regulatory updates. Among these, Cassava Sciences, Inc. SAVA and Lexeo Therapeutics LXEO were down on leadership changes and study results, respectively.The company stated that its priority remains on developing a potentially effective treatment for Alzheimer’s disease and it will do so with transparency, accountability and the highest ethical business practices. SAVA also stated that the ongoing phase III trials are being run according to FDA protocols, and no one from the company knows or will ever know the subjects receiving a drug or placebo. No individual has access to sub-study results and other information that might be used to infer which patients are on placebo.KYV-101 is an autologous, fully human CD19 chimeric antigen receptor  T-cell product candidate for use in B cell-driven autoimmune diseases. SPS is a rare, progressi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QieiOVP5CdM1cfxTnlcVfQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e797ee31d4bee954c41ecfac218dc795","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QieiOVP5CdM1cfxTnlcVfQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e797ee31d4bee954c41ecfac218dc795"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-lxrx-regulatory-133800345.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SAVA","SAVAW","LXEO","BK4535","BK4121","BK4139","BK4022","LXRX","BK4530","BK4230","FA","CAR","BK4547","LU0390134368.USD","BK4007","BK4539","BK4130","KYTX","BK4588","CRL","BK4585"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":-0.9905},{"period":"ytd","weight":-0.9905}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.","exchange":"NASDAQ","name":"Cassava Sciences Warrants","nameEN":"Cassava Sciences Warrants"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cassava Sciences Warrants(SAVAW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cassava Sciences Warrants(SAVAW) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cassava Sciences Warrants,SAVAW,Cassava Sciences Warrants股票,Cassava Sciences Warrants股票老虎,Cassava Sciences Warrants股票老虎国际,Cassava Sciences Warrants行情,Cassava Sciences Warrants股票行情,Cassava Sciences Warrants股价,Cassava Sciences Warrants股市,Cassava Sciences Warrants股票价格,Cassava Sciences Warrants股票交易,Cassava Sciences Warrants股票购买,Cassava Sciences Warrants股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cassava Sciences Warrants(SAVAW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cassava Sciences Warrants(SAVAW) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction